Helicobacter pylori (H. pylori) is a ubiquitous human pathogen that colonizes the gastric mucosa of approximately half the world’s population (1). This gram-negative bacterium has been classified as a Group I carcinogen by the World Health Organization due to its pivotal role in the etiology of various gastric disorders, including chronic gastritis, peptic ulcers, and gastric adenocarcinoma (2, 3). The pathogenesis of H. pylori-associated Gastric cancer (GC) involves a complex interplay between microbial virulence factors, host genetic mutations and immune responses, and other exposure factors, such as high-nitrite diets, culminating in cascade of inflammatory events that can lead to severe gastric pathology.

Upon infection, H. pylori trigger a robust proinflammatory response, resulting in chronic gastritis. Persistent inflammation can induce gastric epithelial cell apoptosis and mucosal atrophy, setting the stage for compensatory hyperplasia and dysregulated cell differentiation. This altered cellular landscape often progresses to intestinal metaplasia, a precursor lesion that may further evolve into dysplasia, carcinoma in situ, and ultimately invasive adenocarcinoma (4–6). Leveraging cutting-edge Artificial intelligence (AI) tools to decipher H. pylori’s antigenic landscape is crucial for developing next-generation precision vaccines to combat H. pylori-associated malignancies.

Gastric Cancer represents a significant global health burden, ranking as the fifth most common cancer worldwide and a leading cause of cancer-related mortality. Analysis of data from The Global Cancer Observatory database (https://gco.iarc.fr/en/projects) reveals striking geographical variations in the age-standardized incidence rate (ASIR) of GC, with particularly high rates observed in Asia and neighboring regions. Notably, countries such as Japan (27.6/100,000), Azerbaijan (16.56/100,000), and China (13.72/100,000) exhibit elevated ASIRs, which are strongly associated with H. pylori infection and dietary factors.

The etiology of GC is multifactorial, with H. pylori infection identified as primary risk factor, alongside alcohol consumption and smoking. Dietary habits, particularly consumption of high-nitrite salt-preserved foods and low-fruit intake (22), like South Korea (26.98/100,000) and North Korea (13.91/100,000). In contrast, regions with lower H. pylori infection rates, such as North America and Europe, demonstrate comparatively lower GC incidence, exemplified by Finland (3.99/100,000) and Canada (4.65/100,000) ( Figure 1 ).

A comprehensive study examining H. pylori infection prevalence and gastric cancer incidence from 1980 to 2022 revealed significant regional variations. The highest infection rates among adults are observed in Africa and the Eastern Mediterranean, while lower rates were reported in Asia and Europe. Countries such as Jordan (88.6%), Ecuador (85.7%), and Guatemala (86.6%) exhibit the highest prevalence of infection. Conversely, countries like Finland (9.1%), and New Zealand (15.0%) demonstrate markedly lower infection rates (23, 24).

The globally prevalence of H. pylori and its role in initiating inflammatory responses that can lead to carcinogenesis underscore the critical need for effective management strategies. This review provides a comprehensive overview of current treatment approaches and explores innovative therapeutic strategies aimed at mitigating H. pylori infection and its associated health risk.

Eradication of H. pylori remain the cornerstone of gastric disease prevention. Current treatment strategies primarily rely on empirical antibiotic regimens, with triple therapy as the gold standard. Despite achieving high eradication rates (>90%) in some populations (25), the global surge in antibiotic resistance poses a significant challenge. Triple therapy is no longer considered the gold standard in many regions (26). This escalating threat has spurred the development of more robust approaches, including quadruple therapy and adjunctive treatments, to combat this resilient pathogen.

Antibiotic resistance poses a formidable challenge to H. pylori eradication and gastric cancer prevention. The resistance primarily stems from point mutations in antimicrobial-associated genes (e.g., rrn23S, pbp-1, rdxA.) and the presence of drug efflux pumps. For instance, mutations in the 23S rRNA can reduce clarithromycin binding affinity, while efflux pumps actively expel antibiotics, maintaining suboptimal intracellular drug concentrations (44, 45). Additionally, H. pylori eradication efficacy is intricately linked to colonization density and virulence factors like cagA and vacA. This pathogen induces gastrointestinal microbiota dysbiosis, altering the host’s susceptibility (46, 47). Notably, Epstein-Barr virus (EB Virus) and H. pylori may synergistically exacerbate gastric inflammation, potentially accelerating carcinogenesis (48). These findings underscore the complex interplay between pathogen, host, and microbiome in H. pylori-associated gastric pathology, highlighting the need for multifaceted therapeutic approaches.

Genetic predisposition plays a crucial role in GC susceptibility. Mutations in the CDH1 and BRCA1/BRCA2 genes significantly increase risk (49). High mutation rates in TP53 (~43%), TTN (~42.5%), and MUC16 (~25.2%) underscore their potential as key drivers of GC (50–52). Additionally, lifestyle factors, such as smoking, alcohol consumption, high-salt/nitrite diets can impede H. pylori eradication and promote GC development (53–55) ( Figure 2 ).

The multifaceted nature of H. pylori infection and its associated cancer risk necessitates innovative therapeutic approaches. Current strategies often fall short of complete eradication, highlighting the urgent need for novel interventions. One promising avenue involves harnessing the host’s adaptive immune system to generate specific, long-lasting memory B and T cells, potentially leading to more efficient H. pylori elimination.

H. pylori infection triggers a sophisticated immune response, orchestrating a complex interplay between innate and adaptive immunity. The innate immune system, acting as the first line of defense, employs pattern recognition receptors (PRRs) on gastric epithelial cells to detect pathogen-associated molecular patterns (PAMPs) (56, 57). This recognition cascade activates NOD-like receptor (NLR) and Toll-like receptors (TLRs), initiating NF-κB signaling and promoting the release of pro-inflammatory cytokines, particularly IL-8 (58).

The adaptive immune response further refines this defense strategy. Type 2 innate lymphocytes (ILC2) secrete IL-5, stimulating B cells to produce IgA, IgG, IgM antibodies. Concurrently, the H. pylori virulence factor CagA induces dendritic cells maturation, facilitating antigens presentation to naïve T cells and their subsequent differentiation into Th1/Th17/Tfh subsets (59).

Paradoxically, H. pylori has evolved mechanisms to subvert this immune assault. By promoting the differentiation of Th17 cells toward regulatory T cells (Tregs), which secrete the anti-inflammatory cytokine IL-10, the bacterium ingeniously establishes immune tolerance, enabling its long-term persistence in the gastric niches ( Figure 3 ) (60). This delicate balance between immune activation and evasion underscores the complexity of H. pylori pathogenesis and highlights potential targets for therapeutic intervention.

The persistence of H. pylori infections, despite initial antibiotic success, underscores a critical challenge in global health. Antibiotic resistance and infection recurrence, particularly in resource-limited settings necessitate innovative strategies for sustainable eradication. Drawing parallels with the transformative impact of Human Papillomavirus (HPV) vaccines on cervical cancer prevention, the development of H. pylori vaccines emerges as a promising frontier in gastric cancer prevention (61, 62).

However, the genetic diversity of H. pylori strains presents a formidable obstacle to vaccine development. This variability, reminiscent of HPV’s subtype complexity, demands a nuanced approach to antigen selection and vaccine design ( Table 1 ). In this context, precision medicine offers valuable insights by identifying strain-specific targets and tailoring immunological strategies accordingly.

Current vaccine candidates target an array of H. pylori antigens can enhance host immunity, despite the delivery method (oral, intranasal mucosal, subcutaneous injection) (68–70), and vaccine composition (primarily peptide vaccines and RNA vaccines) (71, 72). However, they have not yet achieved consistent, long-term protection against H. pylori infection. The immune response against H. pylori primarily orchestrated in the gastric mucosa, where reminiscent of intestinal Peyer’s patches play a crucial role (73). he recognition of bacterial virulence factors or pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors, such as TLR4 or Nod1, triggers the activation of the MyD88-NF-κB pathway and other signaling cascades. This cascade leads to the release of inflammatory cytokines and the initiation of adaptive immune responses, particularly the CD4+ T-cell response.

T-cell assistance facilitates the activation and differentiation of follicular B-cells into plasma cells, which secrete IgA. Secretory IgA is pivotal in mucosal immunity, neutralizing various toxins, while IgG appears to play a less significant role in this context (74). The development of *H. pylori* vaccines have predominantly focused on subunit oral vaccines, designed to efficiently activate mucosal responses. These vaccines, containing single and highly specific peptides devoid of toxic components, theoretically should not elicit long-term intense inflammatory reactions.

Extensive research has demonstrated that oral subunit vaccines generally elicit Th1/Th17 responses and stimulate the production of secretory IgA upon entering the body, significantly enhancing pathogen clearance. However, a clinical trial in China revealed a gradual decline in the protective efficacy of oral vaccines over time, accompanied by decreasing antibody levels (75). Consequently, current research efforts are directed towards enhancing the sustained protective capacity of vaccines, which hinges on the immunogenicity of the vaccine peptides and the selection of appropriate adjuvants.

A recent breakthrough study demonstrated that an LNP-mRNA vaccine for influenza virus maintained superior lung mucosal immune responses compared to protein vaccines, facilitating the formation of germinal center follicular B-cells and memory T-cells (76). This research also highlighted the potential of LNP as a potent immunostimulatory adjuvant, not only for mRNA vaccines but also for enhancing the efficacy of various vaccine types. These findings open new avenues for vaccine development against H. pylori and other mucosal pathogens, potentially revolutionizing our approach to preventive medicine.

Recent advances in vaccine technology offer new avenues for exploration. A multi-epitope oral vaccine, incorporating four H. pylori virulence factors (Urease, NAP, HSP60, and HpaA), showed promising results in murine models, eliciting robust systemic and mucosal immune responses (77). This approach highlights the potential of tailoring comprehensive and multi-target vaccine strategies to overcome the challenges posed by H. pylori’s genetic diversity, a key component of precision therapy approaches.

The virulence of H. pylori strains is intricately linked to genetic factors, particularly the cagA and vacA genes. CagA-positive strains correlate with increased risk of peptic ulcers and gastric cancer, while vacA gene variations (s1/m1, s1/m2, s2/m2) modulate cytotoxicity and disease outcomes (78–82). These findings underscore the importance of tailoring vaccine strategies to address the molecular heterogeneity of H. pylori strains.

Nucleic acid vaccines represent a cutting-edge approach, offering the potential to induce robust humoral and cellular immunity against conserved epitopes across multiple H. pylori subtypes (83–85). This technology circumvents challenges associated with oral vaccine delivery, such as gastric acidity and mucosal immune induction, presenting a promising avenue for future research.

The urgent need to combat H. pylori infection has driven the development of various vaccine candidates ( Table 2 ). Despite extensive efforts, significant success remains elusive. Clinical studies primarily assess vaccine efficacy through measurements of specific antibody levels and post-vaccination adverse reactions. However, a critical gap exists in evaluating the vaccines’ ability to prevent H. pylori infection, limiting our understanding of their real-world effectiveness (70). A notable Phase I/II clinical trial conducted by Peter et al. investigated an oral vaccine containing three recombinant H. pylori antigens: VacA, CagA, and neutrophil-activating protein (NAP). While vaccinated volunteers exhibited significantly higher levels of H. pylori-specific antibodies compared to the control group, the vaccine failed to demonstrate superior infection prevention. Surprisingly, over half of the control group experienced spontaneous infection clearance, highlighting the complexity of H. pylori immunology and the challenges in vaccine development.

The limited efficacy of current vaccines can be attributed to several factors. H. pylori exhibits considerable genetic diversity, particularly in its virulence factors, which display high antigenic variability. Antigens with low conservation between different H. pylori strains are prone to evading immune recognition (86). Moreover, virulence factors targeted by vaccines may be lost following vaccination, rendering the immune response ineffective. The high genetic variability of H. pylori enables rapid adaptation to the selective pressure imposed by vaccination, posing a significant obstacle to vaccine efficacy. Enhancing vaccine immunogenicity while mitigating immune escape mechanisms remains a central challenge in developing effective immunization strategies against H. pylori (87).

The development of universal vaccines with multi-epitope tailored to multi-pathogenic H. pylori subtypes holds significant promise. However, realizing this potential requires overcoming the complexities of antigen variability and immunogenicity assessment. Leveraging advanced bioinformatics and machine learning or Artificial Intelligence algorithms may accelerate the design and optimization of next-generation H. pylori vaccines, potentially revolutionizing our approach to gastric cancer prevention through precision medicine and targeted therapy strategies.

The persistent challenge of H. pylori infection, a Class I carcinogen, contributes to significantly global gastrointestinal diseases. Despite extensive research efforts, conventional therapeutic approaches have been hampered by antibiotic resistance and recurrence, underscoring the urgent need for innovative strategies. This review illuminates the potential of next-generation H. pylori vaccines in bolstering host immunity and mitigating infection-associated gastric cancer risk (1).

While recent advancements in understanding immune mechanisms and inflammatory responses have provided valuable insights, their translation into effective preventive vaccines remains elusive. Although some clinical trials have shown promise, significant hurdles persist, including suboptimal efficacy and adverse effect. We propose a paradigm-shifting approach rooted in precision medicine: the development of tailored, multiepitope antigens targeting diverse H. pylori pathogenic subtypes. By leveraging cutting-edge artificial intelligence tools, we envision the creation of highly specific H. pylori neoantigen vaccines for gastric cancer prevention. This innovative strategy not only promises to address the limitations of current triple-antibiotics therapies, but also has the potential to revolutionize our approach to oncogenic pathogens more broadly. The integration of AI-driven vaccine design with precision therapy concepts opens new avenues for personalized interventions, potentially offering a transformative solution to the global burden of H. pylori-associated diseases.

As we stand at the cusp of this exciting frontier, the convergence of AI, immunology, and precision medicine holds immense promise for reshaping the landscape of infectious disease management and cancer prevention. This approach may serve as a blueprint for tackling other persistent pathogen-associated carcinogenesis, heralding a new era of tailored therapeutic strategies with far-reaching implications for global health.